159 related articles for article (PubMed ID: 7303699)
1. [Therapeutic strategies in the treatment of breast cancer (author's transl)].
Huber H; Gattringer C; Grünewald K; Margreiter R; Mikuz G; Frommhold H; Senn HJ; Braunsteiner H
Wien Klin Wochenschr; 1981 Sep; 93(17):531-41. PubMed ID: 7303699
[TBL] [Abstract][Full Text] [Related]
2. [Role of biological indicators in the therapeutic decision in breast carcinoma].
Amadori D; Maltoni R
Chir Ital; 1995; 47(4):15-22. PubMed ID: 9005127
[TBL] [Abstract][Full Text] [Related]
3. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
4. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
5. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
6. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
7. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
[TBL] [Abstract][Full Text] [Related]
8. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors affecting response to aminoglutethimide in advanced breast cancer.
Brufman G
Anticancer Res; 1993; 13(4):1235-7. PubMed ID: 8352549
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for breast cancer and their use in the clinical setting.
Kapoor A; Vogel VG
Expert Rev Anticancer Ther; 2005 Apr; 5(2):269-81. PubMed ID: 15877524
[TBL] [Abstract][Full Text] [Related]
12. [Hormonreceptors in the therapy concept of breast cancer (author's transl)].
Jonat W; Maass H
Arch Geschwulstforsch; 1981; 51(7):637-41. PubMed ID: 7337546
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of breast cancer based on its specific biological behavior].
Tominaga T
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2718-25. PubMed ID: 3753020
[TBL] [Abstract][Full Text] [Related]
14. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.
Harlan LC; Clegg LX; Abrams J; Stevens JL; Ballard-Barbash R
J Clin Oncol; 2006 Feb; 24(6):872-7. PubMed ID: 16484696
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic value of estrogen receptors in breast cancer (author's transl)].
Reiner G; Jakesz R; Kolb R; Bettelheim P; Bieglmayer C; Spona J
Chir Forum Exp Klin Forsch; 1980; ():315-8. PubMed ID: 7389473
[TBL] [Abstract][Full Text] [Related]
17. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R
Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897
[TBL] [Abstract][Full Text] [Related]
18. [Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial].
Delozier T; Switsers O; Génot JY; Ollivier JM; Héry M; Namer M; Frenay M; Kerbrat P; Julien JP; Naja A; Janvier M; Macé-Lesec'h J
Bull Cancer; 1997 Jan; 84(1):25-30. PubMed ID: 9180855
[TBL] [Abstract][Full Text] [Related]
19. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
Garg AK; Strom EA; McNeese MD; Buzdar AU; Hortobagyi GN; Kuerer HM; Perkins GH; Singletary SE; Hunt KK; Sahin A; Schechter N; Valero V; Tucker SL; Buchholz TA
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):138-45. PubMed ID: 15093909
[TBL] [Abstract][Full Text] [Related]
20. [Effective treatment strategy in elderly breast cancer patients].
Boér K
Orv Hetil; 2005 Jan; 146(1):15-21. PubMed ID: 15715368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
